Bausch Health Companies Inc. (BHC)
- Previous Close
4.7400 - Open
4.7800 - Bid 4.4000 x 3200
- Ask 5.5900 x 3100
- Day's Range
4.6300 - 4.8100 - 52 Week Range
3.9600 - 9.8500 - Volume
2,901,192 - Avg. Volume
2,499,244 - Market Cap (intraday)
1.747B - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1200 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 10, 2010
- 1y Target Est
7.50
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
www.bauschhealth.com20,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BHC
View More
Performance Overview: BHC
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BHC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BHC
View MoreValuation Measures
Market Cap
1.75B
Enterprise Value
22.12B
Trailing P/E
--
Forward P/E
1.30
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.18
Price/Book (mrq)
--
Enterprise Value/Revenue
2.27
Enterprise Value/EBITDA
7.89
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.41%
Return on Assets (ttm)
4.30%
Return on Equity (ttm)
--
Revenue (ttm)
9.73B
Net Income Avi to Common (ttm)
-40M
Diluted EPS (ttm)
-0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
1.13B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
1.56B
Research Analysis: BHC
View MoreResearch Reports: BHC
View MoreDropping Coverage of Bausch Health Companies
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
Placing Both Bausch Entities Under Review Following Mixed Court Ruling on Xifaxan Patent Case
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
RatingPrice TargetEnd of an Era as Papa Leaves Bausch's Board; Shares Still Trade Below FVE After 18% Gain
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
RatingPrice TargetMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
This edition features putting the Bausch & Lomb spinoff under our lens, the regulation of utility companies, wagering on Tabcorp, and International Flavors & Fragrances, BlackRock, and Fortinet.